Texas Begins Lottery Oversight Transition

(Texas Scorecard) – Texas Lottery commissioners are already in the process of transferring oversight of the lottery to the Department of Licensing and Regulation, less than a week after lawmakers voted to abolish the embattled commission.
The early movement is notable, given that Gov. Greg Abbott has not yet signed the Legislature's proposal—Senate Bill 3070—into law.
A TLC spokesperson told Texas Scorecard, 'With the passage of Senate Bill 3070, the Texas Lottery Commission is evaluating next steps in alignment with the bill's intent to transfer regulatory authority to the Texas Department of Licensing and Regulation. While the Commissioners under active terms remain appointed at this time, the agency is actively working on the transition.'
Texas Scorecard attempted to access the website showing information on Texas Lottery commissioners earlier this week but was unable to do so as the commissioner profiles were gone.
After reaching out and receiving a comment from the TLC spokesperson, the website was put back up. However, Commissioner Cindy Lyons Fields, previously listed among the other commissioners, was absent from the site when it returned.
In addition to changing the lottery's overseeing agency, SB 3070 includes new, strict regulations on the purchase of tickets. The measure also establishes an abbreviated sunset review period for the lottery.
The TLC, which has been in existence since 1991, has come under scrutiny over the past months after revelations of rigged jackpots, potential money laundering, and collusion between government agency employees and vendors to game the lottery for profit.
The Texas Lottery is now the subject of multiple state and federal investigations as a result.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Wire

6 hours ago

• Business Wire

OrsoBio to Present Preclinical Data on Mitochondrial Protonophore Portfolio in Models of Obesity at the American Diabetes Association's 85th Scientific Sessions

MENLO PARK, Calif.--(BUSINESS WIRE)--OrsoBio, Inc. ('OrsoBio' or 'the Company'), a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced new preclinical data being presented at the 85th Scientific Sessions of the American Diabetes Association (ADA) being held June 20-23, 2025, in Chicago, Ill. The Company will present three abstracts highlighting the efficacy of its mitochondrial protonophores to induce weight loss and provide glycemic benefits while preserving lean mass in diet-induced obese (DIO) mice. The studies demonstrate the potential of TLC-6740 and TLC-1180—as monotherapy and in combination with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide—for both the induction and maintenance of weight loss following incretin treatment. 'The mechanism of our mitochondrial protonophores to increase energy expenditure complements that of incretins to enhance and sustain weight loss and provide additive metabolic benefits,' said Mani Subramanian, MD, PhD, Chief Executive Officer of OrsoBio. 'These preclinical findings mark an important step in fulfilling our mission to develop innovative, effective, oral therapies for obesity that preserve muscle and support cardiometabolic health.' OrsoBio is advancing a pipeline of novel therapies targeting obesity through mechanistically distinct and complementary approaches. The Company's lead candidates include TLC-6740 and TLC-1180, both mitochondrial protonophores that promote weight loss by increasing energy expenditure. In addition, OrsoBio is developing TLC-3595, a selective inhibitor of acetyl-CoA carboxylase 2 (ACC2), designed to enhance fat oxidation. "GLP-1 receptor agonists have transformed obesity treatment but are limited by gastrointestinal side effects and loss of muscle mass,' said Rob Myers, MD, Chief Medical Officer of OrsoBio. 'Our preclinical data show that our mitochondrial protonophores drive sustained, fat-selective weight loss and metabolic benefits when combined with or sequenced after GLP-1 receptor agonists. These findings support our ongoing Phase 1b study of TLC-6740 in combination with tirzepatide (NCT05822544)." Poster information: Sequential Combination of the Mitochondrial Protonophore TLC-6740 With Semaglutide Normalizes Body Weight and Preserves Lean Mass in DIO Mice Abstract #1687-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study assessed TLC-6740 alone, in combination with low-dose semaglutide (sequential combination), and as maintenance therapy following semaglutide discontinuation in DIO mice. The sequential combination of TLC-6740 with low-dose semaglutide produced superior body weight and fat mass loss, and improved glycemic parameters compared with TLC-6740 alone and high-dose semaglutide. Initiating TLC-6740 after semaglutide discontinuation maintained body weight and fat mass loss, and glycemic benefits. These findings support evaluation of TLC-6740 in combination with incretins in people living with obesity; a 24-week combination study of TLC-6740 with tirzepatide is ongoing (NCT05822544). De Novo or Sequential Combination of the Mitochondrial Protonophore TLC-1180 With Semaglutide Improves Weight Loss and Preserves Lean Mass in DIO Mice Abstract #1694-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study evaluated the effects of TLC-1180 alone, in combination with semaglutide, and as a maintenance treatment following semaglutide discontinuation in DIO mice. As monotherapy, TLC-1180 demonstrated body weight and fat mass loss and preserved lean mass. Body weight and fat mass loss were amplified, and lean mass was preserved with TLC-1180 in combination with semaglutide. These benefits persisted when TLC-1180 was used as a maintenance treatment after semaglutide discontinuation. These data highlight the potential of TLC-1180 as monotherapy, in combination with incretins, or as maintenance therapy post incretin discontinuation in people living with obesity. Novel Combination of a Mitochondrial Protonophore and an Acetyl-CoA Carboxylase 2 (ACC2) Inhibitor Causes Weight Loss and Preserves Lean Mass in Obese Mice Abstract #1686-P Poster Session: Monday, June 23, 2025 (12:30 - 1:30 p.m. CT) This preclinical study evaluated the effects of the mitochondrial protonophore, TLC-1180, and the ACC2 inhibitor, TLC-3595—as monotherapy and in combination—and semaglutide in DIO mice. TLC-3595 dose dependently reduced body weight, fat mass, and liver biochemistry while preserving lean mass in DIO mice. A combination of TLC-3595 with TLC-1180 had similar weight loss efficacy to semaglutide, but preserved lean mass. Taken together, these data suggest that the novel, all-oral, non-incretin combination of TLC-3595 and TLC-1180 may cause similar weight loss to incretins and may afford additional advantages, including improved weight loss quality and/or tolerability (e.g., reduced incidence of gastrointestinal adverse events). About TLC-6740 TLC-6740 is a novel, oral, liver-targeted mitochondrial protonophore in development for the treatment of obesity and obesity-associated diseases, including diabetes and MASH. Based on active hepatic uptake and mitochondrial protonophore activity, TLC-6740 increases energy expenditure in hepatocytes, and is expected to have broad, systemic metabolic and cardiovascular benefits, including weight loss, improved insulin sensitivity, and as a treatment for MASH, and dyslipidemia. TLC-6740 is currently being evaluated in a Phase 1b clinical trial, as monotherapy and in combination with tirzepatide, in patients living with obesity (NCT05822544). About TLC-1180 TLC-1180 is a novel, potent, long-acting mitochondrial protonophore that has been shown to increase energy expenditure in mice with diet-induced obesity (DIO). In preclinical studies of DIO mice, TLC-1180 induced weight loss, improved glucose control, and enhanced the efficacy of GLP-1 receptor agonists, both as a single agent and in combination with incretins. TLC-1180 is currently completing IND-enabling studies and a first-in-human study is expected to initiate in 2025. About TLC-3595 TLC-3595 is a novel and selective ACC2 inhibitor designed to treat obesity and type 2 diabetes by increasing fatty acid oxidation (FAO), reducing ectopic lipid accumulation, and improving insulin sensitivity in skeletal muscle and liver. The compound may also have potential as a treatment for other conditions characterized by impaired FAO, including heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction-associated steatohepatitis (MASH). About OrsoBio, Inc. OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat obesity and obesity-associated disorders, including type 2 diabetes, MASH, and severe dyslipidemias. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism. For more information, please visit

Chicago Tribune

6 hours ago

• Chicago Tribune

Embattled Kenwood shelter housing migrants and homeless Chicagoans to close in coming months

A Kenwood shelter housing both migrants and Chicagoans experiencing homelessness will close in the coming months following a divide amongst neighbors, according to an email update from state Sen. Robert Peters. Located at 4900 S. DuSable Lake Shore Drive, the shelter opened in summer 2023 to accommodate migrants sent to Chicago by Texas Gov. Greg Abbott. Its opening drew sharp pushback from residents concerned about how newcomers from crisis-affected regions would integrate into the neighborhood. Tensions deepened when the facility was later expanded to include homeless Chicagoans, part of the city and state's One System Initiative aimed at merging shelter services for both populations. Early months of combined migrant, homeless shelters in Chicago see success, structural challengesPeters said he was notified of the closure by city and Illinois Department of Human Services officials at 3:15 p.m. Friday. Those currently housed at the shelter will move to new facilities over the next three to six months, he said. Neither the city nor the state was immediately able to provide a comment Friday afternoon regarding the reason for the closure or the number of people affected. 'We've always believed that housing is a human right,' Peters said. 'But also, at the end of the day, what matters most is being transparent with everybody.' As tens of thousands of people arrived by bus over roughly two years, the city and state scrambled to open enough shelters to stave off a full-blown homelessness crisis in Chicago. The city and state were running 28 migrant-exclusive facilities at the peak of arrivals in January of last year, according to city census data. The idea of a combined system was championed by some who said it would spread out resources to a wider range of people. There are dozens of shelters in the new system. The closure announcement also comes as President Donald Trump has ramped up immigration enforcement in and around the city, targeting courts and offices where people are reporting for check-ins. Many of the migrants being housed by the city are from Venezuela, a country that Trump has repeatedly singled out in immigration policy.

Engadget

7 hours ago

• Engadget

NYC proposes 5 percent raise for rideshare drivers in a bid to appease Uber and Lyft

New York City's Taxi and Limousine Commission (TLC) have settled on new minimum-wage rules for rideshare drivers, Bloomberg reports. Drivers will receive a five percent raise under the new proposal, a compromise to keep Uber and Lyft from locking drivers out of their apps. The proposal needs to be voted on by the TLC's board of commissioners before it goes into effect, but assuming it does, it'll end months of uncertainty for drivers working in the city. Uber began sporadically locking drivers out of its app in May 2024, preventing them taking rides and earning money. The company was blocking access to its app to avoid having to pay drivers who were working but not actively taking rides. Besides introducing a minimum wage for drivers that started around $18 per hour in 2022, New York also included stipulations in its law that required drivers be paid for the downtime between rides, something Uber and Lyft naturally had a problem with. Bloomberg writes that the TLC initially proposed a 6.1 percent raise in an attempt to disincentivize Uber and Lyft from locking drivers out. The proposal would adjust how driver pay is calculated, in exchange for an upfront raise and a guarantee that drivers are warned before they lose access to a rideshare app. Settling on a five percent raise and a commitment to not raise wages yearly and instead based "changing industry dynamics," is a further capitulation. One that's still not enough for Lyft, apparently. The company told Bloomberg that, "while these changes are a step in the right direction, we still have concerns that the underlying pay formula will still deprive drivers of earning opportunities, drive up prices for riders and reduce ride availability." Uber and Lyft have long had a contentious relationship with city and state governments over driver protections. In comparison to the passing of Prop 22 in California, which reclassified gig workers as contractors after another law did the opposite, even a diminished minimum wage law in New York is better than nothing.